SOCRA - Society of Clinical Research Associates Society of Clinical Research Associates Adverse Event Safety Reporting 1 — Questions and Answers
Question 1: Which of the following criteria qualifies an adverse event as 'serious' (SAE) under ICH E6 GCP guidelines?
- Any adverse event that causes a subject to miss a scheduled study visit
- An adverse event resulting in death, hospitalization, persistent disability, or congenital anomaly (Correct answer)
- Any adverse event requiring a protocol-specified dose reduction
- An adverse event occurring in more than 5% of the study population
Correct answer: An adverse event resulting in death, hospitalization, persistent disability, or congenital anomaly
ICH E6 defines a serious adverse event as one that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or constitutes an important medical event requiring intervention to prevent one of these outcomes.
Question 2: Under 21 CFR 312.32, who bears primary responsibility for submitting IND safety reports to the FDA?
- The principal investigator at each clinical site
- The IRB or ethics committee overseeing the trial
- The sponsor of the investigational new drug application (Correct answer)
- The clinical research associate assigned to the study
Correct answer: The sponsor of the investigational new drug application
The sponsor holds the IND and is therefore primarily responsible for submitting safety reports to the FDA under 21 CFR 312.32. Investigators report SAEs to the sponsor, who evaluates causality and expectedness before determining whether FDA notification is required.
Question 3: What is the required timeframe for submitting a non-expedited (periodic) IND safety report to the FDA?
- Within 7 calendar days of awareness
- Within 15 calendar days of awareness
- Annually, within 60 days of the IND anniversary date (Correct answer)
- Within 30 calendar days of the end of each study phase
Correct answer: Annually, within 60 days of the IND anniversary date
Annual IND safety reports (non-expedited) must be submitted to the FDA within 60 days of the anniversary of the IND going into effect. These reports provide a cumulative summary of adverse events that do not meet expedited reporting thresholds, unlike 7-day or 15-day reports for unexpected serious suspected adverse reactions.
Question 4: Which form is used in the United States for mandatory reporting of serious adverse events by investigators and manufacturers to the FDA?
- CIOMS I Form
- MedWatch Form 3500A (Correct answer)
- FDA Form 1572
- ICH E2B Individual Case Safety Report
Correct answer: MedWatch Form 3500A
The MedWatch Form 3500A is the FDA's mandatory reporting form for healthcare professionals, manufacturers, and distributors to report serious adverse events. The CIOMS I form is used for international submissions, FDA Form 1572 is the investigator statement of responsibilities, and ICH E2B is an electronic transmission standard.
Question 5: In adverse event causality assessment, what does a 'probable' relationship between an investigational product and an adverse event indicate?
- No plausible biological relationship exists between the drug and the event
- A reasonable causal relationship exists and alternative explanations are unlikely, with the event improving on dechallenge (Correct answer)
- The causal relationship cannot be evaluated due to insufficient information
- The investigational product is the sole confirmed cause of the adverse event
Correct answer: A reasonable causal relationship exists and alternative explanations are unlikely, with the event improving on dechallenge
'Probable' causality means there is a plausible time relationship, alternative explanations are unlikely, and the event typically improves on dechallenge (withdrawal of the drug). It suggests a likely connection but does not reach the certainty of 'definite,' which also requires positive rechallenge or definitive confirmation.
Question 6: When an investigator first becomes aware of an SAE that meets expedited reporting criteria, what is the FIRST required action per ICH E6 and 21 CFR 312.64?
- Submit a MedWatch 3500A report directly to the FDA within 15 days
- Notify the sponsor immediately, typically within 24 hours of awareness (Correct answer)
- Amend the informed consent form before continuing subject enrollment
- Suspend all study activities pending a full IRB safety review
Correct answer: Notify the sponsor immediately, typically within 24 hours of awareness
Investigators must notify the sponsor immediately — typically within 24 hours — upon becoming aware of any SAE, per ICH E6 Section 4.11 and 21 CFR 312.64(b). The sponsor then evaluates the event for causality and expectedness before determining whether and how quickly to report to the FDA. Direct investigator-to-FDA reporting bypasses the sponsor's required safety evaluation role.
SOCRA - Society of Clinical Research Associates Society of Clinical Research Associates Adverse Event Safety Reporting 1
Which of the following criteria qualifies an adverse event as 'serious' (SAE) under ICH E6 GCP guidelines?